NDAORALSUSPENSION, EXTENDED RELEASE
Approved
Dec 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
15
Data completeness
4/8 — Partial
CLONIDINE (clonidine) by Gen Pharmaceuticals is clinical pharmacology clonidine stimulates alpha-adrenoreceptors in the brain stem. First approved in 2009.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Clonidine is an oral extended-release antihypertensive agent that works by stimulating alpha-adrenoreceptors in the brain stem to reduce sympathetic outflow and lower blood pressure. It acts relatively rapidly, with peak effect within 2-4 hours of oral dosing. The drug is indicated for hypertension management in patients requiring sustained blood pressure control.
$33MPart D
LOE ApproachingProduct is approaching loss of exclusivity with modest Part D spending (~$33M), indicating a mature, stable market with limited growth opportunity and likely smaller commercial team.
Mechanism of Action
CLINICAL PHARMACOLOGY Clonidine stimulates alpha-adrenoreceptors in the brain stem. This action results in reduced sympathetic outflow from the central nervous system and in decreases in peripheral resistance, renal vascular resistance, heart rate, and blood pressure. Clonidine hydrochloride…
Worked on CLONIDINE at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.